Inaugural Miami Cancer Institute Precision Oncology Symposium - Evaluation - Day 1 - February 3, 2023

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence

	5	4	3	2	1
Properly diagnose and manage solid tumor malignancies.	Properly diagnose and manage solid tumor malignancies. - 5	Properly diagnose and manage solid tumor malignancies. - 4	Properly diagnose and manage solid tumor malignancies. - 3	Properly diagnose and manage solid tumor malignancies. - 2	Properly diagnose and manage solid tumor malignancies. - 1
Provide an update of new molecular and targeted treatments being developed for solid tumors.	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 5	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 4	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 3	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 2	Provide an update of new molecular and targeted treatments being developed for solid tumors. - 1

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Immunoablative Therapy - Luis Diaz, M.D.	Immunoablative Therapy - Luis Diaz, M.D. - 5	Immunoablative Therapy - Luis Diaz, M.D. - 4	Immunoablative Therapy - Luis Diaz, M.D. - 3	Immunoablative Therapy - Luis Diaz, M.D. - 2	Immunoablative Therapy - Luis Diaz, M.D. - 1
Re-imagining the (R)evolution in the Precision Oncology Paradigm - Vivek Subbiah, M.D.	Re-imagining the (R)evolution in the Precision Oncology Paradigm - Vivek Subbiah, M.D. - 5	Re-imagining the (R)evolution in the Precision Oncology Paradigm - Vivek Subbiah, M.D. - 4	Re-imagining the (R)evolution in the Precision Oncology Paradigm - Vivek Subbiah, M.D. - 3	Re-imagining the (R)evolution in the Precision Oncology Paradigm - Vivek Subbiah, M.D. - 2	Re-imagining the (R)evolution in the Precision Oncology Paradigm - Vivek Subbiah, M.D. - 1
Precision Oncology in Advanced Colorectal Cancer (aCRC) - Tanios Bekaii-Saab, M.D.	Precision Oncology in Advanced Colorectal Cancer (aCRC) - Tanios Bekaii-Saab, M.D. - 5	Precision Oncology in Advanced Colorectal Cancer (aCRC) - Tanios Bekaii-Saab, M.D. - 4	Precision Oncology in Advanced Colorectal Cancer (aCRC) - Tanios Bekaii-Saab, M.D. - 3	Precision Oncology in Advanced Colorectal Cancer (aCRC) - Tanios Bekaii-Saab, M.D. - 2	Precision Oncology in Advanced Colorectal Cancer (aCRC) - Tanios Bekaii-Saab, M.D. - 1
HER2 Targeted Treatments: How Low Can You Go? - Jenny Chang, M.D.	HER2 Targeted Treatments: How Low Can You Go? - Jenny Chang, M.D. - 5	HER2 Targeted Treatments: How Low Can You Go? - Jenny Chang, M.D. - 4	HER2 Targeted Treatments: How Low Can You Go? - Jenny Chang, M.D. - 3	HER2 Targeted Treatments: How Low Can You Go? - Jenny Chang, M.D. - 2	HER2 Targeted Treatments: How Low Can You Go? - Jenny Chang, M.D. - 1
Targeted Therapy for the Management of Cervical Cancer - Thomas Herzog, M.D.	Targeted Therapy for the Management of Cervical Cancer - Thomas Herzog, M.D. - 5	Targeted Therapy for the Management of Cervical Cancer - Thomas Herzog, M.D. - 4	Targeted Therapy for the Management of Cervical Cancer - Thomas Herzog, M.D. - 3	Targeted Therapy for the Management of Cervical Cancer - Thomas Herzog, M.D. - 2	Targeted Therapy for the Management of Cervical Cancer - Thomas Herzog, M.D. - 1
Precision Oncology Approaches in Uncommon Mutations in Lung Cancer - Luis Raez, M.D.	Precision Oncology Approaches in Uncommon Mutations in Lung Cancer - Luis Raez, M.D. - 5	Precision Oncology Approaches in Uncommon Mutations in Lung Cancer - Luis Raez, M.D. - 4	Precision Oncology Approaches in Uncommon Mutations in Lung Cancer - Luis Raez, M.D. - 3	Precision Oncology Approaches in Uncommon Mutations in Lung Cancer - Luis Raez, M.D. - 2	Precision Oncology Approaches in Uncommon Mutations in Lung Cancer - Luis Raez, M.D. - 1
Precision Oncology Approaches in Common Mutations in Lung Cancer - Charu Aggarwal, M.D.	Precision Oncology Approaches in Common Mutations in Lung Cancer - Charu Aggarwal, M.D. - 5	Precision Oncology Approaches in Common Mutations in Lung Cancer - Charu Aggarwal, M.D. - 4	Precision Oncology Approaches in Common Mutations in Lung Cancer - Charu Aggarwal, M.D. - 3	Precision Oncology Approaches in Common Mutations in Lung Cancer - Charu Aggarwal, M.D. - 2	Precision Oncology Approaches in Common Mutations in Lung Cancer - Charu Aggarwal, M.D. - 1
Precision Oncology Approaches in Phase 1 Trials - Nagla Karim, M.D.	Precision Oncology Approaches in Phase 1 Trials - Nagla Karim, M.D. - 5	Precision Oncology Approaches in Phase 1 Trials - Nagla Karim, M.D. - 4	Precision Oncology Approaches in Phase 1 Trials - Nagla Karim, M.D. - 3	Precision Oncology Approaches in Phase 1 Trials - Nagla Karim, M.D. - 2	Precision Oncology Approaches in Phase 1 Trials - Nagla Karim, M.D. - 1
Endometrial Cancer Therapy During the Era of Precision Medicine - Roisin O'Cearbhaill, M.D.	Endometrial Cancer Therapy During the Era of Precision Medicine - Roisin O'Cearbhaill, M.D. - 5	Endometrial Cancer Therapy During the Era of Precision Medicine - Roisin O'Cearbhaill, M.D. - 4	Endometrial Cancer Therapy During the Era of Precision Medicine - Roisin O'Cearbhaill, M.D. - 3	Endometrial Cancer Therapy During the Era of Precision Medicine - Roisin O'Cearbhaill, M.D. - 2	Endometrial Cancer Therapy During the Era of Precision Medicine - Roisin O'Cearbhaill, M.D. - 1
Gastrointestinal Stromal Tumors: The GIST of Precision Medicine - Jonathan Trent, M.D.	Gastrointestinal Stromal Tumors: The GIST of Precision Medicine - Jonathan Trent, M.D. - 5	Gastrointestinal Stromal Tumors: The GIST of Precision Medicine - Jonathan Trent, M.D. - 4	Gastrointestinal Stromal Tumors: The GIST of Precision Medicine - Jonathan Trent, M.D. - 3	Gastrointestinal Stromal Tumors: The GIST of Precision Medicine - Jonathan Trent, M.D. - 2	Gastrointestinal Stromal Tumors: The GIST of Precision Medicine - Jonathan Trent, M.D. - 1
Role of Precision Medicine in the Management of Ovarian Cancer - John Diaz, M.D.	Role of Precision Medicine in the Management of Ovarian Cancer - John Diaz, M.D. - 5	Role of Precision Medicine in the Management of Ovarian Cancer - John Diaz, M.D. - 4	Role of Precision Medicine in the Management of Ovarian Cancer - John Diaz, M.D. - 3	Role of Precision Medicine in the Management of Ovarian Cancer - John Diaz, M.D. - 2	Role of Precision Medicine in the Management of Ovarian Cancer - John Diaz, M.D. - 1
Targeted Therapy for ER+/HER2-MBC: CDK4/6 Inhibition and Beyond - Reshma Mahtani, D.O.	Targeted Therapy for ER+/HER2-MBC: CDK4/6 Inhibition and Beyond - Reshma Mahtani, D.O. - 5	Targeted Therapy for ER+/HER2-MBC: CDK4/6 Inhibition and Beyond - Reshma Mahtani, D.O. - 4	Targeted Therapy for ER+/HER2-MBC: CDK4/6 Inhibition and Beyond - Reshma Mahtani, D.O. - 3	Targeted Therapy for ER+/HER2-MBC: CDK4/6 Inhibition and Beyond - Reshma Mahtani, D.O. - 2	Targeted Therapy for ER+/HER2-MBC: CDK4/6 Inhibition and Beyond - Reshma Mahtani, D.O. - 1
Dividing and Conquering Sarcomas Through Precision Oncology - Neeta Somaiah, M.D.	Dividing and Conquering Sarcomas Through Precision Oncology - Neeta Somaiah, M.D. - 5	Dividing and Conquering Sarcomas Through Precision Oncology - Neeta Somaiah, M.D. - 4	Dividing and Conquering Sarcomas Through Precision Oncology - Neeta Somaiah, M.D. - 3	Dividing and Conquering Sarcomas Through Precision Oncology - Neeta Somaiah, M.D. - 2	Dividing and Conquering Sarcomas Through Precision Oncology - Neeta Somaiah, M.D. - 1
Precision Oncology in Brain Metastases: Past, Present and Future - Manmeet Ahluwalia, M.D.	Precision Oncology in Brain Metastases: Past, Present and Future - Manmeet Ahluwalia, M.D. - 5	Precision Oncology in Brain Metastases: Past, Present and Future - Manmeet Ahluwalia, M.D. - 4	Precision Oncology in Brain Metastases: Past, Present and Future - Manmeet Ahluwalia, M.D. - 3	Precision Oncology in Brain Metastases: Past, Present and Future - Manmeet Ahluwalia, M.D. - 2	Precision Oncology in Brain Metastases: Past, Present and Future - Manmeet Ahluwalia, M.D. - 1

Was this course fair, balanced and without commercial bias? *

Yes

If you checked "No,” please explain why: *

As a result of my participation in this Symposium, I commit to make the following changes to my clinical practice: *

I will discuss the rationale for new targeted diagnostics and therapeutic strategies for lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcoma and brain tumors.

I will review the role and timing of diagnostic tests, molecular profiling and potential combinations of targeted therapy treatment options.

I will implement the use of plasma-based liquid biopsy approaches for molecular testing.

I will implement monitoring treatment responses for HPV ctDNA.

Not applicable to my practice.

I do not agree with the recommendations presented.

I am retired.

What, if any, new skills/strategies will you apply in your clinical practice? *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so? *

Please provide any additional comments or suggestions.

Name *

Attestation *

Choose 1 option

I attest that I have participated in this live symposium in its entirety.

I attest that I have participated in _____ hours of instruction during this live symposium.

hours attestation *

Hours attended

Leave this field blank

You are here

Inaugural Miami Cancer Institute Precision Oncology Symposium - Evaluation - Day 1 - February 3, 2023